Teva asks Fed Circ for ‘skinny label’ redo
12-10-2021
Fed Circuit split over $235m skinny label verdict
10-08-2021
Skinny-label ruling will ‘decimate’ Hatch-Waxman, Fed Circuit told
05-01-2021
JHVEphoto / Shutterstock.com
Teva has urged the US Court of Appeals for the Federal Circuit to rehear its dispute with GlaxoSmithKline (GSK) en banc, claiming that if the decision is upheld, “every skinny-labelled generic is at risk”.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Federal Circuit, Teva, GlaxoSmithKline, GSK, patent infringement, generic, Coreg, induced infringement, skinny labels
